Terms: = Endocrine gland cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
101 results:
1. Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma.
Sun T; Gilani S; Jain D; Cai G
Diagn Cytopathol; 2023 Nov; 51(11):674-683. PubMed ID: 37469257
[TBL] [Abstract] [Full Text] [Related]
2. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
Hicks HM; Pozdeyev N; Sams SB; Pugazhenthi U; Bales ES; Hofmann MC; McKenna LR; Schweppe RE
Mol Cancer Res; 2023 Sep; 21(9):867-880. PubMed ID: 37219859
[TBL] [Abstract] [Full Text] [Related]
3. Mass Spectrometry-Based Proteomics of Epithelial Ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
4. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
Sánchez-Fdez A; Matilla-Almazán S; Montero JC; Del Carmen S; Abad M; García-Alonso S; Bhattacharya S; Calar K; de la Puente P; Ocaña A; Pandiella A; Esparís-Ogando A
Clin Transl Med; 2023 Apr; 13(4):e1217. PubMed ID: 37029785
[TBL] [Abstract] [Full Text] [Related]
5. MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition.
Silvis MR; Silva D; Rohweder R; Schuman S; Gudipaty S; Truong A; Yap J; Affolter K; McMahon M; Kinsey C
J Exp Med; 2023 Mar; 220(3):. PubMed ID: 36719686
[TBL] [Abstract] [Full Text] [Related]
6. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic cancer Growth.
Erice O; Narayanan S; Feliu I; Entrialgo-Cadierno R; Malinova A; Vicentini C; Guruceaga E; Delfino P; Trajkovic-Arsic M; Moreno H; Valencia K; Blanco E; Macaya I; Öhlund D; Khatri P; Lecanda F; Scarpa A; Siveke JT; Corbo V; Ponz-Sarvise M; Vicent S
Clin Cancer Res; 2023 Mar; 29(6):1137-1154. PubMed ID: 36607777
[TBL] [Abstract] [Full Text] [Related]
7. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian cancers to MEK Inhibition.
Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
[TBL] [Abstract] [Full Text] [Related]
8. Novel Therapeutics for Advanced Differentiated Thyroid cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract] [Full Text] [Related]
9. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report.
Ardalan B; Azqueta JI; England J; Eatz TA
Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34667063
[TBL] [Abstract] [Full Text] [Related]
10. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
[TBL] [Abstract] [Full Text] [Related]
11. BRAF
Traversi F; Stooss A; Dettmer MS; Charles RP
Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
[No Abstract] [Full Text] [Related]
12. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract] [Full Text] [Related]
13. Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition.
Brannon A; Drouillard D; Steele N; Schoettle S; Abel EV; Crawford HC; Pasca di Magliano M
Sci Rep; 2020 Jul; 10(1):11133. PubMed ID: 32636409
[TBL] [Abstract] [Full Text] [Related]
14. APE1 Promotes Pancreatic cancer Proliferation through GFRα1/Src/ERK Axis-Cascade Signaling in Response to GDNF.
Choi YD; Jung JY; Baek M; Khan S; Song PI; Ryu S; Koo JY; Chauhan SC; Tsin A; Choi C; Kim WJ; Kim M
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32438692
[TBL] [Abstract] [Full Text] [Related]
15. Phase 1 study of the pan-HER inhibitor dacomitinib plus the mek1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM; van Brummelen EMJ; Eskens FALM; Huijberts SCFA; de Vos FYFL; Lolkema MPJK; Devriese LA; Opdam FL; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Br J Cancer; 2020 Apr; 122(8):1166-1174. PubMed ID: 32147669
[TBL] [Abstract] [Full Text] [Related]
16. Dietary compound glycyrrhetinic acid suppresses tumor angiogenesis and growth by modulating antiangiogenic and proapoptotic pathways in vitro and in vivo.
Li J; Tang F; Li R; Chen Z; Lee SM; Fu C; Zhang J; Leung GP
J Nutr Biochem; 2020 Mar; 77():108268. PubMed ID: 31830590
[TBL] [Abstract] [Full Text] [Related]
17. Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways.
Zhang X; Hou G; Liu A; Xu H; Guan Y; Wu Y; Deng J; Cao X
Cell Death Dis; 2019 Oct; 10(10):770. PubMed ID: 31601793
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of lncRNA-mRNA networks after mek1/2 inhibition based on WGCNA in pancreatic ductal adenocarcinoma.
Qian J; Yang J; Liu X; Chen Z; Yan X; Gu H; Xue Q; Zhou X; Gai L; Lu P; Shi Y; Yao N
J Cell Physiol; 2020 Apr; 235(4):3657-3668. PubMed ID: 31583713
[TBL] [Abstract] [Full Text] [Related]
19. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract] [Full Text] [Related]
20. Exogenous Hydrogen Sulfide Regulates the Growth of Human Thyroid Carcinoma Cells.
Wu D; Li J; Zhang Q; Tian W; Zhong P; Liu Z; Wang H; Wang H; Ji A; Li Y
Oxid Med Cell Longev; 2019; 2019():6927298. PubMed ID: 31223424
[TBL] [Abstract] [Full Text] [Related]
[Next]
